Diabetes is a money making machine
Current estimates suggest that sales of diabetes-related treatments will increase from $35 billion to $58 billion by 2030.
The following financial information was released by fool.com on November 6, 2012:
“Novo Nordisk controls a quarter of the global diabetes market and in 2011 alone, diabetes products brought in $8 billion for the company. There are estimates that revenues could exceed $20 billion by 2018.”
“Sanofi maintains an 18% market share in diabetes treatments bringing in $5 billion in 2011.”
“Diabetes treatments will remain a growth industry, and the companies that will move to the forefront are those developing products with greater convenience for the consumer.”
“Steady growth markets tend to draw cartoon dollar signs over the eyes of big Pharma players.”
Full post: http://www.fool.com/investing/general/2012/11/06/5-companies-dominating-diabetes.aspx